Dhuwit awis saben siji saham Nanobiotix S.A. (NBTX)

Lambang korporat lan logo Nanobiotix S.A. (NBTX)

Nanobiotix S.A. (NBTX) is developing NBTXR3 radio-enhancer particles to combat tumors, leveraging a partnership with Janssen. Cash per share demonstrates liquidity dynamics, where the value of 2.50 reflects this status. Regulatory complexities and financial pressure create certain risks, while AI accelerates drug modeling, although final tests remain the responsibility of physicians.

Dana dhuwit saben saham Nanobiotix Group (NBTX): kanggo periode 04.07.2022 - 20.11.2026

Rincian analitis perusahaan Nanobiotix S.A.

- rega saham lan prakiraan rega para ahli:
- rincian posisi dhuwit lan arus kas:
Analisis komprehensif perusahaan:NBTX (Nanobiotix Corp)
Barang utama Nanobiotix SA

This metric measures the volume of liquid resources per common share, allowing for an assessment of the business's actual solvency and the risk of capital degradation hidden behind the asset's apparent cheapness. Analyzing the trend of cash per share serves as a portfolio stress-testing tool, confirming the ability of Nanobiotix S.A. (NBTX) to fund the diversification of clinical programs for treating various solid tumors without a critical dependence on external borrowings.